Microorganisms and cancer: Quest for a therapy

Journal of Bacteriology

Volumn 185, Issue 9, 2003, Pages 2683-2686

  Chakrabarty, A M ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BCG VACCINE; DESOXYEPOTHILONE B; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; MACROLIDE; UNCLASSIFIED DRUG;

CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CLOSTRIDIUM; LISTERIA MONOCYTOGENES; MICROORGANISM; MYCOBACTERIUM BOVIS; NOTE; PRIORITY JOURNAL; SALMONELLA ENTERICA; TOXOPLASMA GONDII;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL PROTEINS; BACTERIAL VACCINES; BIOLOGICAL THERAPY; HUMANS; NEOPLASMS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; LISTERIA; LISTERIA MONOCYTOGENES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; SALMONELLA; SALMONELLA ENTERICA; TOXOPLASMA GONDII;

EID: 0037408429     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.185.9.2683-2686.2003     Document Type: Note

References (40)

1. Agarwala, S. S., and J. M. Kirkwood. 1998. Adjuvant therapy of melanoma. Semin. Surg. Oncol. 14:302-310.
2. Alexandroff, A. D., A. M. Jackson, M. A. O'Donnell, and K. James. 1999. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689-1694.
3. Brandau, S., J. Riemensberger, M. Jacobsen, D. Kemp, et al. 2001. NK cells are essential for effective BCG immunotherapy. Int. J. Cancer 92:697-702.
4. Chou, T.-C., X.-G. Zhang, A. Balog, D.-S. Su, K. Savin, J. R. Bertino, and S. J. Danishefsky. 1998. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. USA 95:9642-9647.
5. Clarkson, B. D., M. D. Dowling, T. S. Gee, I. B. Cunningham, and A. H. Burchenal. 1975. Treatment of acute leukemia in adults. Cancer 36:775-795.
6. Coley, W. B. 1991. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. 262:3-13.
7. Cover, T. L., and M. J. Blaser. 1995. Helicobacter pylori: a bacterial cause of gastritis, peptic ulcer disease, and gastric cancer. ASM News 61:21-26.
8. Dang, L. H., C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 98:15155-15160.
9. Eisenstein, T. K., B. Bushnell, J. J. Meissler, Jr., N. Dalal, R. Schafer, and H. F. Havas. 1995. Immunotherapy of a plasmacytoma with attenuated Salmonella. Med. Oncol. 12:103-108.
10. Fox, M. E., M. J. Lemmon, M. L. Mauchline, T. O. Davis, A. J. Giaccia, N. P. Minton, and J. M. Brown. 1996. Anaerobic bacteria asa as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther. 3:173-178.
11. Gill, G. V., and A. Holden. 1996. A malignant pleural effusion infected with Salmonella enteritidis. Thorax 51:104-105.
12. Goto, M., T. Yamada, K. Kimbara, J. Horner, et al. 2003. Induction of apoptosis in macrophages by Pseudomonas aeruginosa azurin: tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. Mol. Microbiol. 47:549-559.
13. Haley, J., D. Young, A. Alexandroff, K. James, and A. M. Jackson. 1999. Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology 96:114-121.
14. Hunter, C. A., D. Yu, M. Gee, C. V. Ngo, et al. 2001. Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J. Immunol. 166:5878-5881.
15. Jain, R. K., and N. S. Forbes. 2001. Can engineered bacteria help control cancer? Proc. Natl. Acad. Sci. USA 98:14748-14750.
16. Lamm, D. L., D. E. Thor, S. C. Harris, J. A. Reyna, V. D. Stogdill, and H. M. Radwin. 1980. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol. 124:38-40.
17. Lamm, D. L., D. R. Riggs, J. S. Shriver, P. F. van Gilder, J. F. Rach, and J. I. DeHaven. 1994. Megadose vitamins in bladder cancer: a double-blind clinical trial. J. Urol. 151:21-26.
18. Matsumoto, M., T. Seya, S. Kikkawa, S. Tsuji, et al. 2002. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int. Immunopharmacol. 1:1559-1569.
19. Morales, A., D. Edinger, and A. W. Bruce. 1976. Intracavity Bacillus Calmette Guerin in the treatment of superficial bladder tumours. J. Urol. 116:180-183.
20. Nauts, H. C., W. E. Swift, and B. L. Coley. 1946. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M. D., reviewed in the light of modern research. Cancer Res. 6:205-216.
21. O'Donnell, M. A., and W. C. DeWolf. 1995. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg. Oncol. Clin. N. Am. 4:189-201.
22. Paglia, P., and C. A. Guzman. 1998. Keeping the immune system alerted against cancer. Cancer Immunol. Immunother. 46:88-92.
23. Pan, Z.-K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1:471-477.
24. Parr, I., E. Wheeler, and P. Alexander. 1973. Similarities of the antitumor actions of endotoxin, lipid A and double stranded RNA. Br. J. Cancer 27:370-389.
25. Pawelek, J. M., S. Sodi, A. K. Chakraborty, J. J. Platt, et al. 2002. Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther. 9:813-818.
26. Pawelek, J. M., K. B. Low, and D. Bermudes. 1997. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537-4544.
27. Punj, V., and A. M. Chakrabarty. Redox proteins in mammalian cell death: an evolutionarily conserved function in mitochondria and prokaryotes. Cell. Microbiol., in press.
28. Ratlift, T. L., J. K. Ritchey, J. J. Yuan, G. L. Andriole, and W. J. Catalona. 1993. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150:1018-1023.
29. Ribi, E. E., D. L. Granger, K. C. Millner, and S. M. Strain. 1975. Tumor regression caused by endotoxins and mycobacterial fractions. J. Natl. Cancer Inst. 55:1253-1257.
30. Shear, M. J., and A. Perrault. 1944. Chemical treatment of tumors. IX: Reaction of mice with primary subcutaneous tumors to injection of the hemorrhage-producing bacteria polysaccharide. J. Natl. Cancer Inst. 4:461-476.
31. Shepherd, F. A. 1997. Alternative to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer 17:S121-S136.
32. Sizemore, D. R., A. A. Branstrom, and J. C. Sadoff. 1995. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270:299-302.
33. Strausser, H. R., and L. A. Bober. 1972. Inhibition of tumor growth and survival of aged mice inoculated with Moloney tumor transplants and treated with endotoxin. Cancer Res. 32:2156-2159.
34. Sznol, M., S. L. Lin, D. Bermudes, L.-M. Zheng, and I. King. 2000. Use of preferentially-replicating bacteria for the treatment of cancer. J. Clin. Investig. 105:1027-1030.
35. Thanhauser, A., A. Bohle, B. Schneider, et al. 1995. The induction of Bacillus Calmette-Guerin-activated killer cells requires the presence of monocytes and T helper type-1 cells. Cancer Immunol. Immunother. 40:103-108.
36. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
37. Weth, R., O. Christ, S. Stevanovic, and M. Zoler. 2001. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther. 8:599-611.
38. Wood, D. W., J. C. Setubal, R. Kaul, D. E. Monks, J. P. Kitajima, V. K. Okura, et al. 2001. The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science 294:2317-2323.
39. Yamada, T., M. Goto, V. Punj, O. Zaborina, et al. 2002. The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53. Infect. Immun. 70:7054-7062.
40. Yamada, T., M. Goto, V. Punj, O. Zaborina, et al. 2002. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA 99:14098-14103.